These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12474639)

  • 1. Hyperoxaluric calcium nephrolithiasis.
    Asplin JR
    Endocrinol Metab Clin North Am; 2002 Dec; 31(4):927-49. PubMed ID: 12474639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
    Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diet and renal stone formation.
    Trinchieri A
    Minerva Med; 2013 Feb; 104(1):41-54. PubMed ID: 23392537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.
    Noori N; Honarkar E; Goldfarb DS; Kalantar-Zadeh K; Taheri M; Shakhssalim N; Parvin M; Basiri A
    Am J Kidney Dis; 2014 Mar; 63(3):456-63. PubMed ID: 24560157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperoxaluria in patients with idiopathic calcium nephrolithiasis.
    Trinchieri A; Ostini F; Nespoli R; Rovera F; Zanetti G; Pisani E
    J Nephrol; 1998; 11 Suppl 1():70-2. PubMed ID: 9604817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria.
    Sikora P; von Unruh GE; Beck B; Feldkötter M; Zajaczkowska M; Hesse A; Hoppe B
    Kidney Int; 2008 May; 73(10):1181-6. PubMed ID: 18337715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutritional aspects of stone disease.
    Hess B
    Endocrinol Metab Clin North Am; 2002 Dec; 31(4):1017-30, ix-x. PubMed ID: 12474643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
    Jaeger P; Portmann L; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1783-6. PubMed ID: 3798070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Scheinman JI; Voziyan PA; Belmont JM; Chetyrkin SV; Kim D; Hudson BG
    Urol Res; 2005 Nov; 33(5):368-71. PubMed ID: 16292584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL; Nakada SY
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion.
    Crivelli JJ; Mitchell T; Knight J; Wood KD; Assimos DG; Holmes RP; Fargue S
    Nutrients; 2020 Dec; 13(1):. PubMed ID: 33379176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors.
    Laminski NA; Meyers AM; Kruger M; Sonnekus MI; Margolius LP
    Br J Urol; 1991 Nov; 68(5):454-8. PubMed ID: 1747716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D; Hoppe B; Groothoff J
    Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
    Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
    J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic markers in calcium nephrolithiasis--current and traditional ideas with a new look].
    Hess B
    Schweiz Med Wochenschr; 1995 Dec; 125(51-52):2460-70. PubMed ID: 8571096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of stone disease.
    Delvecchio FC; Preminger GM
    Curr Opin Urol; 2003 May; 13(3):229-33. PubMed ID: 12692447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers.
    Chai W; Liebman M; Kynast-Gales S; Massey L
    Am J Kidney Dis; 2004 Dec; 44(6):1060-9. PubMed ID: 15558527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
    Osther PJ
    Scand J Urol Nephrol; 1999 Dec; 33(6):368-71. PubMed ID: 10636575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.